Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results

-- - Conference call scheduled for April 20, 2015 at 8:00 a.m. ET -

  • Date: 2015-04-20
  • Pageview: 12967

 

BEIJINGApril 20, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products inChina, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2014.

Fourth Quarter 2014 Financial Highlights

(Compared to the fourth quarter 2013)

  • Quarterly sales were $20.3 million, a decrease of 11.4% from $22.9 million in the prior year period. Excluding revenue recognized from the stockpiling of H5N1 pandemic influenza vaccine of $0.1 million in the fourth quarter of 2014 and $7.2 million in the fourth quarter of 2013, the Company's fourth quarter 2014 regular product sales were $20.2 million, an increase of 28.2% from $15.8 million in the prior year period.  
  • Gross profit was $15.1 million, an increase of 2.9% from $14.7 million in the prior year period. Excluding H5N1 vaccine sales, gross margin was 75.3% in the fourth quarter of 2014, compared to 60.4% in the prior year period.
  • Net income attributable to common stockholders was $1.3 million, or $0.02 per basic and diluted share for the fourth quarter of 2014, compared to $5.8 million, or $0.10 per basic and diluted share, for the fourth quarter of 2013.

Full Year 2014 Financial Highlights

(Compared to the full year 2013)

  • Total sales were $63.1 million, a decrease of 13.0% from $72.5 million in the prior year. Excluding revenue recognized from the stockpiling of H5N1 pandemic influenza vaccine of $0.2 million in 2014 and $10.7 million in 2013, the Company's annual sales of regular products were $62.9 million, an increase of 1.8% from $61.8 million in the prior year. 
  • Gross profit was $46.6 million, a decrease of 9.1% from $51.3 million in the prior year. Excluding H5N1 vaccine sales, gross margin was 74.2% in 2014, compared to 72.6% in 2013.
  • Net loss attributable to common stockholders was $0.9 million, or $(0.02) per basic and diluted share in 2014, compared to a net income attributable to common shareholders of $7.4 million, or $0.13 per basic and diluted share in 2013. 

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "Although the overall vaccine market environment was challenging in 2014, total sales of our regular products increased by 1.8% year-over-year, which is in line with our expectations. This growth is primarily due to increased sales of our hepatitis A&B vaccine, Bilive, in the private-pay market, as well as our hepatitis A vaccine, Healive, and seasonal flu vaccine, Anflu, in the public-pay market.

"We continue to make progress on our pipeline vaccines. We have submitted all required supplementary documentation for our EV71 vaccine candidate and are in the final stages of the approval process. We had begun clinical trials on our pneumococcal polysaccharide vaccine (PPV) at the beginning of April 2015. In the fourth quarter of 2014, we submitted our investigational new drug application for our proprietary hepatitis B vaccine and a new generation of hepatitis A & B combination vaccine to the China Food and Drug Administration (CFDA). Most recently, in January 2015, our pneumococcal conjugate vaccine (PCV) was approved to begin human clinical trials. We believe the advancement of our pipeline programs will serve as catalysts for future growth of the Company."

Fourth Quarter 2014 Business Highlights

Sales Update

Public Tenders. Sinovac has been a supplier of the seasonal flu vaccines for the Beijing Center for Disease Control (CDC)'s immunization program for the past eight years. During the 2014-2015 flu season, the Company was one of four suppliers of the flu vaccines in Beijing and its share of this tender increased to 40% from 23% in the 2013-2014 flu season, representing a total tender value of approximately $1.9 million.

As previously announced, Sinovac was selected by the Tianjin CDC to be the sole supplier of inactivated hepatitis A vaccines to the Expanded Immunization Program (EPI) in Tianjin for years from 2015 to 2017. The total value of this tender is approximately RMB 28 million ($4.6 million) over three years.

Seasonal Influenza Vaccine Registration License in ChileAs previously announced, Sinovac obtained a registration license for its seasonal influenza vaccine from Chile's Institute of Public Health. The license is valid until October 2019.

R&D Update

EV71 vaccine. In January 2015, the Company submitted supplementary documentation to the CFDA, as required following review of the new drug application (NDA) by an expert panel in November 2014. Currently, Sinovac is waiting for the results of the review by CFDA regarding supplementary documentations.

Pneumococcal 23-valent polysaccharide vaccine (PPV). The Company obtained its clinical trial license in May 2014. Sinovac had started trials at the beginning of April 2015.

Varicella vaccine. The Company is currently preparing supplementary materials for the clinical trial application, following review by an expert panel in November 2014. The Company expects to receive its clinical trial approval in 2015.

Pneumococcal 13-valent conjugate vaccine (PCV). The Company obtained its clinical trial license in January 2015, having filed its application with the CFDA in March 2011.

Sabin-inactivated polio vaccine (sIPV). The clinical trial application for the sIPV vaccine was accepted by Beijing Food and Drug Administration in October 2014 and the vaccine is currently under review by the CFDA .  

Hepatitis B vaccine and new generation of hepatitis A & B vaccine. The Company has completed pre-clinical studies for its proprietary hepatitis B vaccine and filed a clinical trial application in December 2014. Simultaneously, Sinovac is developing a new generation of its hepatitis A & B combination vaccine based on its monovalent hepatitis A and hepatitis B vaccines.

Rubella vaccine. The Company obtained the clinical trial license in December 2014, and expects to develop this vaccine as a measles, mumps and rubella (MMR) combination vaccine.

Unaudited Financial Results for Fourth Quarter 2014

   

2014 Q4

% of Sales

2013 Q4

% of Sales

(In USD'000 except percentage data)

Hepatitis A -- Healive

 

10,997

54.2%

7,970

34.7%

Hepatitis A&B -- Bilive

 

6,321

31.1%

2,846

12.4%

Influenza vaccine

 

2,423

11.9%

3,409

14.9%

Animal vaccine

 

22

0.1%

617

2.7%

Mumps vaccine

 

456

2.2%

934

4.1%

Regular sales

 

20,219

99.5%

15,776

68.8%

H5N1 vaccine

 

100

0.5%

7,169

31.2%

Total sales

 

20,319

100.0%

22,945

100.0%

Cost of goods sold

 

5,204

25.6%

8,255

36.0%

Gross profit

 

15,115

74.4%

14,690

64.0%

Quarterly sales were $20.3 million, a decrease of 11.4% from $22.9 million in the fourth quarter of 2013. Excluding revenue of the Company's H5N1 vaccine under the government stockpiling program, regular sales were $20.2 million in the fourth quarter of 2014, an increase of 28.2% over $15.8 million in the prior year period. The increase was primarily driven by increased sales of the Company's hepatitis vaccines, due to increased demand in the private-pay market as well as an increase in average selling price .

Gross profit was $15.1 million, an increase of 2.9% from $14.7 million in the prior year period. Excluding the impact from H5N1 vaccine revenue, gross margin was 75.3%, compared to 60.4% in the prior year period. The increase in gross margin was primarily driven by the improved efficiency in the Company's manufacturing processes, which resulted in lower unit costs, as well as increased selling prices of some of the Company's products.

Selling, general and administrative expenses for the fourth quarter of 2014 were $9.9 million, compared to $7.9 million in the same period of 2013. The increase was primarily due to the trial production of EV71 as well as foreign exchange loss due to the appreciation of the US dollar against the Chinese RMB.

R&D expenses for the fourth quarter of 2014 were $3.5 million, a $1.1 million increase over the same period in 2013. This increase was attributable to the continued advancement of Sinovac's pipeline products, including preclinical development and milestone payment of sIPV and trial production of PPV.

Net income attributable to common stockholders was $1.3 million, or $0.02 per basic and diluted share, compared to $5.8 million, or$0.10 per basic and diluted share, for the fourth quarter of 2013.

Unaudited Financial Results for Full Year 2014

   

2014

% of 
Sales

2013

% of 
Sales

(In USD'000 except percentage data)

Hepatitis A -- Healive

 

26,515

42.0%

26,420

36.4%

Hepatitis A&B -- Bilive

 

21,935

34.8%

20,782

28.7%

           

Influenza vaccine

 

12,131

19.2%

12,156

16.8%

Animal vaccine

 

169

0.3%

750

1.0%

Mumps vaccine

 

2,150

3.4%

1,680

2.3%

Regular sales

 

62,900

99.7%

61,788

85.2%

H5N1 vaccine

 

201

0.3%

10,736

14.8%

Total sales

 

63,101

100.0%

72,524

100.0%

Cost of goods sold

 

16,493

26.1%

21,273

29.3%

Gross profit

 

46,608

73.9%

51,251

70.7%

Total sales in 2014 were $63.1 million, a decrease of 13.0% from $72.5 million. Excluding the impact from one-time H5N1 vaccine revenue recognition in 2013, the Company's annual sales of regular products increased by 1.8% year over year. The growth was mainly due to the sales of hepatitis A&B vaccines in the private-pay market, as well as sales of hepatitis A vaccines and the seasonal flu vaccine in the public-pay market.

Gross profit of 2014 was $46.6 million, a decrease of 9.1% from $51.3 million in 2013. Gross margin was 73.9%, compared to 70.7% in the prior year period. Excluding the impact from H5N1 vaccine, gross margin was 74.2% in 2014, compared to 72.6% in 2013.The increase in gross margin was primarily driven by the improved efficiency in the Company's manufacturing processes, which resulted in lower unit costs.

Selling, general and administrative expenses for 2014 were $34.8 million, consistent with expenses of $34.5 million in 2013.

R&D expenses for 2014 were $11.0 million, compared to $8.4 million in 2013. The increase in the R&D expenses was primarily related to the continued development of the Company's pipeline vaccine candidates, including the preclinical development and milestone payment for sIPV, and trial production of PPV.

Net loss attributable to stockholders in 2014 was $0.9 million or $(0.02) per basic and diluted share, compared to net income of $7.4 million, or $0.13 per basic and diluted share in 2013.

Balance Sheet Highlights

As of December 31, 2014, cash, cash equivalents totaled $90.0 million, compared to $107.2 million as of December 31, 2013. Net cash used in operating activities was $8.6 million in 2014. Net cash used in investing activities was $12.5million, which was primarily used for payment of property, plant and equipment for the Company's PPV and varicella production facilities. Net cash provided by financing activities was $5.2 million in 2014, including proceeds from loans of $17.8 million which were offset by repayment of loans of$16.6 million, as well as $3.5 million in government grant received. As of December 31, 2014, the Company had $47.4 million of bank loans due within one year. Sinovac's cash and cash equivalents and time deposit position of $91.5 million are sufficient to meet both these loan repayment obligations and the Company's operational requirements. When appropriate, the Company will seek new commercial bank loans to finance the commercialization of pipeline products.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. Sinovac has filed a new drug application with the China Food & Drug Administration for its proprietary enterovirus 71 vaccine, having been proven effective in preventing hand, foot and mouth disease in infants and children during its Phase III clinical trial. The Company is currently developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported select vaccines toMexicoMongoliaNepal, and the Philippines, and was recently granted a license to commercialize its hepatitis A vaccine in Chile. For more information, please visit the Company's website at www.sinovac.com.

Contact

Sinovac Biotech Ltd. 
Helen Yang / Chris Lee 
Tel: +86-10-8279-9659 / 9696 
Fax: +86-10-6296-6910 
Email: ir@sinovac.com

ICR Inc. 
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com

SINOVAC BIOTECH LTD.

   

Consolidated Balance sheets

   

As of December 31, 2014 and 2013

   

(Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data)

     

Current assets 

December 31, 2014

December 31, 2013

     

Cash and cash equivalents

90,018

107,242

Time deposit

1,500

-

Accounts receivable -- net

40,757

31,927

Inventories

18,832

14,329

Prepaid expenses and deposits 

1,430

1,150

Deferred tax assets

2,266

2,602

Total current assets

154,803

157,250

     

Property, plant and equipment

68,417

67,963

Prepaid land lease payments

10,405

10,948

Long-term inventories

2,648

2,781

Long-term prepaid expenses

3

154

Prepayments for acquisition of equipment

1,387

708

Deferred tax assets

515

117

Licenses

352

772

Total assets

238,530

240,693

     

Current liabilities

   

Bank loans and current portion of long-term debt

47,375

16,217

Loan from a non-controlling shareholder

2,595

3,324

Accounts payable and accrued liabilities 

23,237

28,037

Income tax payable

1,101

246

Deferred revenue

4,996

875

Deferred government grants

530

458

     

Total current liabilities

79,834

49,157

     

Deferred government grants

7,494

4,746

Long-term debt

1,803

32,146

Deferred revenue

7,191

11,005

Other non-current liabilities

482

-

Total long term liabilities

16,970

47,897

     

Total liabilities

96,804

97,054

     

Commitments and contingencies 

   

Equity

   

Preferred stock

-

-

Common stock

56

56

Additional paid-in capital

108,243

107,393

Accumulated other comprehensive income

12,022

14,141

Statutory surplus reserves

12,627

11,808

Accumulated deficit

(6,384)

(4,714)

Total stockholders' equity

126,564

128,684

     

Non-controlling interests

15,162

14,955

Total equity

141,726

143,639

Total liabilities and equity

238,530

240,693

 

 SINOVAC BIOTECH LTD. 

 Consolidated Statements of Comprehensive Income (loss) 

 For the three and twelve months ended December 31, 2014 and 2013

 (Unaudited) 

 (Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data)

             
   

 Three months ended December 31 

 

 Twelve months ended December 31 

   

2014

2013

 

2014

2013

 Sales 

 

20,319

22,945

 

63,101

72,524

 Cost of sales 

 

5,204

8,255

 

16,493

21,273

 Gross profit 

 

15,115

14,690

 

46,608

51,251

             

 Selling, general and administrative expenses 

 

9,891

7,894

 

34,787

34,538

 Provision (recovery) for doubtful accounts 

 

(170)

(1,561)

 

329

(504)

 Research and development expenses 

 

3,522

2,461

 

11,034

8,384

 Loss on disposal and impairment of property, plant
and equipment

 

44

91

 

74

88

Government grants recognized in income

 

(104)

-

 

(104)

-

 Total operating expenses 

 

13,183

8,885

 

46,120

42,506

 Operating income 

 

1,932

5,805

 

488

8,745

             

 Interest and financing expenses  

 

(920)

(863)

 

(3,407)

(3,031)

 Interest income

 

565

600

 

2,685

2,168

 Other income 

 

1,177

121

 

1,356

263

 Income before income taxes and non-controlling interests  

 

2,754

5,663

 

1,122

8,145

 Income tax benefit (expense) 

 

(616)

2,287

 

(1,458)

2,225

             

 Net Income (loss) 

 

2,138

7,950

 

(336)

10,370

Less: (Income) attributable to the non-controlling interests

(834)

(2,129)

 

(515)

(2,928)

 Net Income (loss) attributable to stockholders of Sinovac 

 

1,304

5,821

 

(851)

7,442

             

 Other comprehensive income (loss), net of tax of nil 

           

Foreign currency translation adjustments

 

(988)

1,086

 

(2,427)

2,686

 Total comprehensive income (loss) 

 

1,150

9,036

 

(2,763)

13,056

  Less: comprehensive (income) attributable to non-controlling interests  

 

(699)

(2,279)

 

(207)

(3,244)

 Comprehensive income (loss) attributable to stockholders of Sinovac 

 

451

6,757

 

(2,970)

9,812

             

 Weighted average number of shares of 

           

   Basic 

 

55,749,040

55,497,357

 

55,681,076

55,301,276

   Diluted 

 

56,106,941

56,057,462

 

55,681,076

55,802,338

             

 Earning (loss) per share 

           

   Basic 

 

0.02

0.10

 

(0.02)

0.13

   Diluted 

 

0.02

0.10

 

(0.02)

0.13

 

SINOVAC BIOTECH LTD.

Consolidated Statements of Cash Flows

For the three and twelve months ended December 31, 2014 and 2013

(Unaudited)

(Expressed in thousands of U.S. Dollars)

 

Three months ended

 

Twelve months ended 

 

 December 31

 

 December 31

   

2014

 

2013

   

2014

 

2013

Cash flows provided by (used in) operating activities

                 

Net income (loss)

$

2,138

$

7,950

 

$

(336)

$

10,370

  Adjustments to reconcile net income (loss) to net cash

                 

  provided by (used in) operating activities:

                 

 - deferred income taxes

 

(707)

 

(2,287)

   

(162)

 

(2,225)

 - stock-based compensation

 

72

 

72

   

287

 

281

 - inventory provision

 

689

 

629

   

1,273

 

1,399

 - provision(recovery) for doubtful accounts

 

(170)

 

(1,561)

   

329

 

(504)

 - loss (gain) on disposal and impairment of equipment 

 

44

 

(349)

   

74

 

88

 - deferred government grant recognized in income

 

(104)

 

-

   

(104)

 

-

 - depreciation of property, plant and equipment and amortization of licenses

2,872

 

1,706

   

8,142

 

6,433

 - amortization of the prepaid land lease payments

 

80

 

-

   

278

 

311

 - accretion expenses

 

29

 

47

   

114

 

100

Changes in:

                 

 - accounts receivable

 

(284)

 

8,197

   

(9,691)

 

(7,256)

 - inventories

 

638

 

(1,624)

   

(6,170)

 

(7,547)

 - income tax payable 

 

602

 

-

   

899

 

7

 - prepaid expenses and deposits

 

277

 

415

   

(496)

 

242

 - deferred revenue 

 

1,217

 

4,037

   

601

 

(675)

 - accounts payable and accrued liabilities

 

(374)

 

2,684

   

(4,167)

 

4,552

 - other non-current liablitites

 

482

 

-

   

482

 

-

Net cash provided by (used in) operating activities

 

7,501

 

19,916

   

(8,647)

 

5,576

                   

Cash flows provided by (used in) financing activities

                 

 - Proceeds from bank loan

 

-

 

2,942

   

17,837

 

16,800

 - Repayments of bank loan

 

(5,957)

 

(3,927)

   

(15,962)

 

(4,089)

 - Proceeds from issuance of common stock,

                 

   net of share issuance costs

 

176

 

281

   

512

 

848

 - Proceeds from shares subscribed 

 

45

 

(196)

   

51

 

18

 - Government grants received 

 

91

 

149

   

3,520

 

842

 - Repayment of loan from a non-controlling shareholder

 

(649)

 

-

   

(649)

 

-

                   

Net cash provided (used in) by financing activities

 

(6,294)

 

(751)

   

5,309

 

14,419

                   

Cash flows used in investing activities

                 

 - Acquisition of property, plant and equipment

 

(3,696)

 

(1,739)

   

(11,003)

 

(5,176)

 - Time deposit placed with financial institution

 

(1,500)

 

-

   

(1,500)

 

-

                   

Net cash used in investing activities

 

(5,196)

 

(1,739)

   

(12,503)

 

(5,176)

                   

Exchange gain (loss) on cash and cash equivalents

 

(347)

 

790

   

(1,383)

 

1,182

                   

Increase (decrease) in cash and cash equivalents

 

(4,336)

 

18,216

   

(17,224)

 

16,001

                   

Cash and cash equivalents, beginning of year

 

94,354

 

89,026

   

107,242

 

91,241

                   

Cash and cash equivalents, end of year

$

90,018

$

107,242

 

$

90,018

$

107,242

                   
                   
                   
                   

 

SOURCE Sinovac Biotech Ltd.

 

 

       
     
   

RELATED CONTENT

 

Bookmark and Share

Copyright © 2001-2015 Sinovac Biotech Ltd. All Rights Reserved.

Add: No. 39 Shangdi Xi Road, Haidian District, Beijing, P.R.C. 100085 Supported by elongtian